Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 19, 2026, 10:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 210 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Immune Checkpoint Inhibitors Clear all
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

NCT07079631
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
BNT314, Pumitamig, SoC chemotherapy treatment 1, SoC chemotherapy treatment 2, Bevacizumab
Biological · Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
4
States / cities
New Haven, Connecticut • Grand Rapids, Michigan • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 19, 2026, 10:21 AM EDT
Terminated Not applicable Interventional

Bronchoscopy With Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune Checkpoint Inhibitors in Patients With Non-small Cell or Small Cell Lung Cancer

NCT02937402
View directory record Official record
Conditions
Non-Small Cell Lung Carcinoma, Small Cell Lung Carcinoma
Interventions
Bronchoscopy with Bronchoalveolar Lavage, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
19 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Jul 19, 2026, 10:21 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer

NCT04670445
View directory record Official record
Conditions
Stage IV Melanoma, Advanced Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Unresectable Non-Small Cell Lung Carcinoma, Unresectable Stage III Non-Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage, Stage IV Merkel Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma, Stage IV Basal Cell Carcinoma, Stage IV Breast Cancer, Stage IV Colorectal Cancer, Stage IV Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Hepatocellular Cancer, Stage IV Renal Cell Carcinoma, Stage IV Bladder Cancer, Stage IV Head and Neck Squamous Cell Carcinoma, Stage IV Cervical Cancer, Stage IV Endometrial Cancer, Stage IV Mesothelioma, Immunotherapy, Immune Checkpoint Inhibitors
Interventions
Educational Video and QPL List, Usual Care
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Jul 19, 2026, 10:21 AM EDT
Not listed Phase 1 Interventional

Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors

NCT03385486
View directory record Official record
Conditions
Stage III Melanoma, Stage IV Melanoma
Interventions
TBX-3400
Biological
Lead sponsor
Taiga Biotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Jul 19, 2026, 10:21 AM EDT
Recruiting No phase listed Observational

Decoupling Immunotherapy Toxicity and Cancer Response

NCT07382752
View directory record Official record
Conditions
Tumor, Cardiovascular
Interventions
Not listed
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 19, 2026, 10:21 AM EDT
Recruiting Phase 2 Interventional

Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial

NCT06841705
View directory record Official record
Conditions
Immune Checkpoint Inhibitor-Related Colitis
Interventions
Vedolizumab 300 MG Injection [Entyvio], Prednisone (and methylprednisolone), Prednisone Taper, Placebo Prednisone Capsules, Placebo Vedolizumab, Sulfamethoxazole-Trimethoprim, Placebo for Sulfamethoxazole-Trimethoprim
Drug · Other
Lead sponsor
Shilpa Grover, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Jul 19, 2026, 10:21 AM EDT
Active, not recruiting Phase 3 Interventional

Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

NCT06790966
View directory record Official record
Conditions
Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck, Unresectable Head and Neck Squamous Cell Carcinoma
Interventions
Combination Treatment of PDS0101 and Pembrolizumab, Pembrolizumab Monotherapy
Combination Product · Drug
Lead sponsor
PDS Biotechnology Corp.
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
28
States / cities
Phoenix, Arizona • Greenbrae, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jul 19, 2026, 10:21 AM EDT
Recruiting Phase 1Phase 2 Interventional

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

NCT04691817
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell
Interventions
Atezolizumab, Tocilizumab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 19, 2026, 10:21 AM EDT
Terminated Phase 1 Interventional

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

NCT05069935
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
FT538, Cyclophosphamide, Fludarabine, Monoclonal antibody - Dose Escalation, Monoclonal antibody - Dose Expansion
Drug · Combination Product
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Hackensack, New Jersey • Nashville, Tennessee • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Jul 19, 2026, 10:21 AM EDT
Recruiting Phase 3 Interventional

A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

NCT06699212
View directory record Official record
Conditions
Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
ASP-1929 Photoimmunotherapy, Pembrolizumab, Carboplatin, Cisplatin, 5-fluorouracil, Paclitaxel, Docetaxel
Combination Product · Biological · Drug
Lead sponsor
Rakuten Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
Duarte, California • Miami, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jul 19, 2026, 10:21 AM EDT
Not yet recruiting Early Phase 1 Interventional

MCE Molecular Imaging for ICI Myocarditis

NCT07538544
View directory record Official record
Conditions
Immune Checkpoint Inhibitor Myocarditis
Interventions
Myocardial contrast echocardiography molecular imaging for inflammation
Diagnostic Test
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jul 19, 2026, 10:21 AM EDT
Completed No phase listed Observational

Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy

NCT06089967
View directory record Official record
Conditions
Cancer, Immune-related Adverse Event
Interventions
Medical chart review
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Jul 19, 2026, 10:21 AM EDT
Not yet recruiting Phase 2 Interventional

Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases

NCT07043608
View directory record Official record
Conditions
Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic, Clear Cell Renal Cancer, Bone Metastases of a Malignant Tumor, Clear Cell Renal Cell Carcinoma, Bone, Metastatic Cancer, Metastatic Cancer, Metastatic Renal Cell Carcinoma, Metastases to Bone
Interventions
Zanzalintinib, Investigator Choice of Bone Strengthening Agents (BSA), Non-Investigational Radiation Therapy (RT), Bone Scan, Computerized tomography (CT) Scan
Drug · Radiation · Procedure
Lead sponsor
Kelly Fitzgerald, MD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 19, 2026, 10:21 AM EDT
Active, not recruiting No phase listed Observational

A Pilot Study of Blood-based Biomarkers for Response to Immune Checkpoint Inhibitors

NCT06630429
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Renal Cell Carcinoma (RCC)
Interventions
Biospecimen Collection
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Timeline
2020 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jul 19, 2026, 10:21 AM EDT
Active, not recruiting Phase 1 Interventional

Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1

NCT05222932
View directory record Official record
Conditions
Melanoma, Head and Neck Squamous Cell Carcinoma
Interventions
TILT-123, Avelumab
Biological · Drug
Lead sponsor
TILT Biotherapeutics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Jul 19, 2026, 10:21 AM EDT
Recruiting Phase 1Phase 2 Interventional

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

NCT05482893
View directory record Official record
Conditions
Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)
Interventions
Spevatamig (PT886), Paclitaxel, Gemcitabine, Abraxane, KEYTRUDA® (pembrolizumab), FOLFOX, CAPOX, FOLFIRINOX
Drug
Lead sponsor
Phanes Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
11
States / cities
Duarte, California • Los Angeles, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 19, 2026, 10:21 AM EDT
Active, not recruiting No phase listed Observational

Biomarkers of Immune-Related Toxicity

NCT03409016
View directory record Official record
Conditions
Cancer, Metastatic Cancer
Interventions
Blood Testing
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Jul 19, 2026, 10:21 AM EDT
Completed Phase 1 Interventional

Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors

NCT04169321
View directory record Official record
Conditions
Solid Tumor, Unspecified, Adult, Lymphoma
Interventions
Single Arm
Drug
Lead sponsor
Cytosite Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Birmingham, Alabama • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Jul 19, 2026, 10:21 AM EDT
Recruiting No phase listed Observational

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

NCT04751396
View directory record Official record
Conditions
Ankylosing Spondylitis, Autoimmune Disease, Crohn Disease, Enteropathic Arthritis, Enteropathic Spondylitis, Inflammatory Bowel Disease, Melanoma, Psoriasis, Psoriatic Arthritis, Reactive Arthritis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Ulcerative Colitis
Interventions
Best Practice, Educational Intervention, Interview, Questionnaire Administration, Survey Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 19, 2026, 10:21 AM EDT
Completed No phase listed Observational

Immuno-Oncology Database and Bioregistry

NCT04656873
View directory record Official record
Conditions
Malignancy, Immune System Diseases, Autoimmune Diseases
Interventions
Biospecimen Collection, Medical Chart Review, Questionnaires/Surveys
Procedure · Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 19, 2026, 10:21 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

NCT02484404
View directory record Official record
Conditions
Colorectal Neoplasms, Breast Neoplasms
Interventions
Olaparib, Cediranib, Durvalumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 19, 2026, 10:21 AM EDT
Recruiting No phase listed Observational

Cancer-related Fatigue During Maintenance Immunotherapy for Non-small Cell Lung Cancer (NSCLC): a Qualitative Study

NCT06567704
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Interviews
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Jul 19, 2026, 10:21 AM EDT
Completed Not applicable Interventional

Microbial Diversity Between Inflamed and Non-inflamed Skin of Patients With Immune Checkpoint Inhibitor-Induced Dermatitis

NCT04812197
View directory record Official record
Conditions
Genito-Urinary Neoplasm
Interventions
Biospecimen Collection(Punch Biopsy)
Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Jul 19, 2026, 10:21 AM EDT
Completed Phase 2 Interventional Results available

Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC

NCT03041311
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Trilaciclib, Placebo, Carboplatin, Etoposide, Atezolizumab
Drug
Lead sponsor
G1 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
23
States / cities
Beverly Hills, California • Fullerton, California • Loma Linda, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Jul 19, 2026, 10:21 AM EDT